nodes	percent_of_prediction	percent_of_DWPC	metapath
Nabumetone—PTGS2—Risedronate—osteoporosis	0.401	0.649	CbGbCtD
Nabumetone—CYP1A2—Estropipate—osteoporosis	0.115	0.186	CbGbCtD
Nabumetone—CYP1A2—Conjugated Estrogens—osteoporosis	0.0542	0.0878	CbGbCtD
Nabumetone—CYP1A2—Estradiol—osteoporosis	0.0476	0.0771	CbGbCtD
Nabumetone—MPO—Selenium Micronutrient Network—PRDX3—osteoporosis	0.00203	0.0543	CbGpPWpGaD
Nabumetone—Melatonin—CYP19A1—osteoporosis	0.00151	0.521	CrCbGaD
Nabumetone—PTGS2—Synthesis of 15-eicosatetraenoic acid derivatives—GPX1—osteoporosis	0.00146	0.0392	CbGpPWpGaD
Nabumetone—Melatonin—ESR1—osteoporosis	0.00139	0.479	CrCbGaD
Nabumetone—PTGS1—Prostaglandin Synthesis and Regulation—ANXA2—osteoporosis	0.00136	0.0364	CbGpPWpGaD
Nabumetone—PTGS2—Prostaglandin Synthesis and Regulation—ANXA2—osteoporosis	0.00108	0.0289	CbGpPWpGaD
Nabumetone—MPO—C-MYB transcription factor network—COL1A2—osteoporosis	0.00106	0.0285	CbGpPWpGaD
Nabumetone—MPO—C-MYB transcription factor network—WNT1—osteoporosis	0.000966	0.0259	CbGpPWpGaD
Nabumetone—MPO—Vitamin B12 Metabolism—SOD2—osteoporosis	0.000851	0.0228	CbGpPWpGaD
Nabumetone—PTGS1—Selenium Micronutrient Network—PRDX3—osteoporosis	0.000829	0.0222	CbGpPWpGaD
Nabumetone—PTGS2—Calcium signaling in the CD4+ TCR pathway—NFATC1—osteoporosis	0.000769	0.0206	CbGpPWpGaD
Nabumetone—MPO—Vitamin B12 Metabolism—MTHFR—osteoporosis	0.00075	0.0201	CbGpPWpGaD
Nabumetone—MPO—Folate Metabolism—SOD2—osteoporosis	0.000693	0.0186	CbGpPWpGaD
Nabumetone—MPO—Folate Metabolism—GPX1—osteoporosis	0.000661	0.0177	CbGpPWpGaD
Nabumetone—PTGS2—Selenium Micronutrient Network—PRDX3—osteoporosis	0.000658	0.0176	CbGpPWpGaD
Nabumetone—MPO—Folate Metabolism—MTHFR—osteoporosis	0.00061	0.0163	CbGpPWpGaD
Nabumetone—MPO—IL23-mediated signaling events—IL1B—osteoporosis	0.000575	0.0154	CbGpPWpGaD
Nabumetone—PTGS1—Phase 1 - Functionalization of compounds—CYP27A1—osteoporosis	0.000553	0.0148	CbGpPWpGaD
Nabumetone—MPO—Selenium Micronutrient Network—SOD2—osteoporosis	0.00055	0.0147	CbGpPWpGaD
Nabumetone—MPO—Selenium Micronutrient Network—GPX1—osteoporosis	0.000525	0.0141	CbGpPWpGaD
Nabumetone—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—NFATC1—osteoporosis	0.000497	0.0133	CbGpPWpGaD
Nabumetone—MPO—Selenium Micronutrient Network—MTHFR—osteoporosis	0.000485	0.013	CbGpPWpGaD
Nabumetone—MPO—Vitamin B12 Metabolism—IL1B—osteoporosis	0.000445	0.0119	CbGpPWpGaD
Nabumetone—MPO—IL23-mediated signaling events—TNF—osteoporosis	0.000417	0.0112	CbGpPWpGaD
Nabumetone—Urticaria—Ibandronate—osteoporosis	0.000395	0.00115	CcSEcCtD
Nabumetone—Malaise—Zoledronate—osteoporosis	0.000393	0.00115	CcSEcCtD
Nabumetone—Body temperature increased—Ibandronate—osteoporosis	0.000393	0.00115	CcSEcCtD
Nabumetone—Abdominal pain—Ibandronate—osteoporosis	0.000393	0.00115	CcSEcCtD
Nabumetone—Confusional state—Pamidronate—osteoporosis	0.000393	0.00115	CcSEcCtD
Nabumetone—Vertigo—Zoledronate—osteoporosis	0.000392	0.00114	CcSEcCtD
Nabumetone—PTGS2—Defective AMN causes hereditary megaloblastic anemia 1—ACP5—osteoporosis	0.000391	0.0105	CbGpPWpGaD
Nabumetone—Syncope—Zoledronate—osteoporosis	0.000391	0.00114	CcSEcCtD
Nabumetone—Leukopenia—Zoledronate—osteoporosis	0.00039	0.00114	CcSEcCtD
Nabumetone—Anaphylactic shock—Pamidronate—osteoporosis	0.000389	0.00114	CcSEcCtD
Nabumetone—Oedema—Pamidronate—osteoporosis	0.000389	0.00114	CcSEcCtD
Nabumetone—Haemoglobin—Estradiol—osteoporosis	0.000388	0.00113	CcSEcCtD
Nabumetone—Urticaria—Calcitriol—osteoporosis	0.000387	0.00113	CcSEcCtD
Nabumetone—Haemorrhage—Estradiol—osteoporosis	0.000386	0.00113	CcSEcCtD
Nabumetone—Palpitations—Zoledronate—osteoporosis	0.000385	0.00113	CcSEcCtD
Nabumetone—Body temperature increased—Calcitriol—osteoporosis	0.000385	0.00112	CcSEcCtD
Nabumetone—Abdominal pain—Calcitriol—osteoporosis	0.000385	0.00112	CcSEcCtD
Nabumetone—Angioedema—Conjugated Estrogens—osteoporosis	0.000383	0.00112	CcSEcCtD
Nabumetone—Shock—Pamidronate—osteoporosis	0.000383	0.00112	CcSEcCtD
Nabumetone—Loss of consciousness—Zoledronate—osteoporosis	0.000383	0.00112	CcSEcCtD
Nabumetone—Hypersensitivity—Estropipate—osteoporosis	0.000382	0.00112	CcSEcCtD
Nabumetone—Thrombocytopenia—Pamidronate—osteoporosis	0.000381	0.00111	CcSEcCtD
Nabumetone—Vomiting—Etidronic acid—osteoporosis	0.000381	0.00111	CcSEcCtD
Nabumetone—Cough—Zoledronate—osteoporosis	0.00038	0.00111	CcSEcCtD
Nabumetone—Rash—Etidronic acid—osteoporosis	0.000378	0.0011	CcSEcCtD
Nabumetone—Dermatitis—Etidronic acid—osteoporosis	0.000377	0.0011	CcSEcCtD
Nabumetone—Vertigo—Conjugated Estrogens—osteoporosis	0.000377	0.0011	CcSEcCtD
Nabumetone—Hyperhidrosis—Pamidronate—osteoporosis	0.000376	0.0011	CcSEcCtD
Nabumetone—Syncope—Conjugated Estrogens—osteoporosis	0.000376	0.0011	CcSEcCtD
Nabumetone—Hypertension—Zoledronate—osteoporosis	0.000376	0.0011	CcSEcCtD
Nabumetone—Hypersensitivity—Alendronate—osteoporosis	0.000376	0.0011	CcSEcCtD
Nabumetone—Headache—Etidronic acid—osteoporosis	0.000375	0.0011	CcSEcCtD
Nabumetone—Asthenia—Estropipate—osteoporosis	0.000372	0.00109	CcSEcCtD
Nabumetone—Visual impairment—Estradiol—osteoporosis	0.000372	0.00109	CcSEcCtD
Nabumetone—Anorexia—Pamidronate—osteoporosis	0.000371	0.00108	CcSEcCtD
Nabumetone—Palpitations—Conjugated Estrogens—osteoporosis	0.000371	0.00108	CcSEcCtD
Nabumetone—Insomnia—Risedronate—osteoporosis	0.000371	0.00108	CcSEcCtD
Nabumetone—Anxiety—Zoledronate—osteoporosis	0.00037	0.00108	CcSEcCtD
Nabumetone—Loss of consciousness—Conjugated Estrogens—osteoporosis	0.000369	0.00108	CcSEcCtD
Nabumetone—Paraesthesia—Risedronate—osteoporosis	0.000368	0.00107	CcSEcCtD
Nabumetone—Pruritus—Estropipate—osteoporosis	0.000367	0.00107	CcSEcCtD
Nabumetone—Discomfort—Zoledronate—osteoporosis	0.000367	0.00107	CcSEcCtD
Nabumetone—Asthenia—Alendronate—osteoporosis	0.000366	0.00107	CcSEcCtD
Nabumetone—Hypersensitivity—Ibandronate—osteoporosis	0.000366	0.00107	CcSEcCtD
Nabumetone—Cough—Conjugated Estrogens—osteoporosis	0.000366	0.00107	CcSEcCtD
Nabumetone—CYP1A2—Estrogen Receptor Pathway—ESR1—osteoporosis	0.000366	0.0098	CbGpPWpGaD
Nabumetone—Dyspnoea—Risedronate—osteoporosis	0.000365	0.00107	CcSEcCtD
Nabumetone—Erythema multiforme—Estradiol—osteoporosis	0.000365	0.00107	CcSEcCtD
Nabumetone—Dry mouth—Zoledronate—osteoporosis	0.000363	0.00106	CcSEcCtD
Nabumetone—Fatigue—Ethinyl Estradiol—osteoporosis	0.000362	0.00106	CcSEcCtD
Nabumetone—MPO—Folate Metabolism—IL1B—osteoporosis	0.000362	0.0097	CbGpPWpGaD
Nabumetone—Pruritus—Alendronate—osteoporosis	0.000361	0.00106	CcSEcCtD
Nabumetone—Dyspepsia—Risedronate—osteoporosis	0.000361	0.00105	CcSEcCtD
Nabumetone—Tinnitus—Estradiol—osteoporosis	0.00036	0.00105	CcSEcCtD
Nabumetone—Constipation—Ethinyl Estradiol—osteoporosis	0.000359	0.00105	CcSEcCtD
Nabumetone—Confusional state—Zoledronate—osteoporosis	0.000359	0.00105	CcSEcCtD
Nabumetone—Hypersensitivity—Calcitriol—osteoporosis	0.000358	0.00105	CcSEcCtD
Nabumetone—Asthenia—Ibandronate—osteoporosis	0.000357	0.00104	CcSEcCtD
Nabumetone—Anxiety—Conjugated Estrogens—osteoporosis	0.000356	0.00104	CcSEcCtD
Nabumetone—Nausea—Etidronic acid—osteoporosis	0.000356	0.00104	CcSEcCtD
Nabumetone—Anaphylactic shock—Zoledronate—osteoporosis	0.000356	0.00104	CcSEcCtD
Nabumetone—Oedema—Zoledronate—osteoporosis	0.000356	0.00104	CcSEcCtD
Nabumetone—Diarrhoea—Estropipate—osteoporosis	0.000355	0.00104	CcSEcCtD
Nabumetone—Fatigue—Risedronate—osteoporosis	0.000353	0.00103	CcSEcCtD
Nabumetone—Insomnia—Pamidronate—osteoporosis	0.000352	0.00103	CcSEcCtD
Nabumetone—Pruritus—Ibandronate—osteoporosis	0.000352	0.00103	CcSEcCtD
Nabumetone—Constipation—Risedronate—osteoporosis	0.00035	0.00102	CcSEcCtD
Nabumetone—Shock—Zoledronate—osteoporosis	0.00035	0.00102	CcSEcCtD
Nabumetone—Paraesthesia—Pamidronate—osteoporosis	0.00035	0.00102	CcSEcCtD
Nabumetone—Diarrhoea—Alendronate—osteoporosis	0.000349	0.00102	CcSEcCtD
Nabumetone—Asthenia—Calcitriol—osteoporosis	0.000349	0.00102	CcSEcCtD
Nabumetone—Thrombocytopenia—Zoledronate—osteoporosis	0.000348	0.00102	CcSEcCtD
Nabumetone—Dyspnoea—Pamidronate—osteoporosis	0.000347	0.00101	CcSEcCtD
Nabumetone—Feeling abnormal—Ethinyl Estradiol—osteoporosis	0.000346	0.00101	CcSEcCtD
Nabumetone—Chills—Estradiol—osteoporosis	0.000346	0.00101	CcSEcCtD
Nabumetone—Somnolence—Pamidronate—osteoporosis	0.000346	0.00101	CcSEcCtD
Nabumetone—PTGS2—C-MYB transcription factor network—COL1A2—osteoporosis	0.000345	0.00926	CbGpPWpGaD
Nabumetone—Pruritus—Calcitriol—osteoporosis	0.000344	0.00101	CcSEcCtD
Nabumetone—Hyperhidrosis—Zoledronate—osteoporosis	0.000344	0.001	CcSEcCtD
Nabumetone—Gastrointestinal pain—Ethinyl Estradiol—osteoporosis	0.000344	0.001	CcSEcCtD
Nabumetone—Diarrhoea—Raloxifene—osteoporosis	0.000344	0.001	CcSEcCtD
Nabumetone—Dyspepsia—Pamidronate—osteoporosis	0.000343	0.001	CcSEcCtD
Nabumetone—Dizziness—Estropipate—osteoporosis	0.000343	0.001	CcSEcCtD
Nabumetone—Anaphylactic shock—Conjugated Estrogens—osteoporosis	0.000343	0.001	CcSEcCtD
Nabumetone—Oedema—Conjugated Estrogens—osteoporosis	0.000343	0.001	CcSEcCtD
Nabumetone—Alopecia—Estradiol—osteoporosis	0.000341	0.000996	CcSEcCtD
Nabumetone—Diarrhoea—Ibandronate—osteoporosis	0.00034	0.000994	CcSEcCtD
Nabumetone—Anorexia—Zoledronate—osteoporosis	0.000339	0.000991	CcSEcCtD
Nabumetone—Decreased appetite—Pamidronate—osteoporosis	0.000339	0.000989	CcSEcCtD
Nabumetone—PTGS1—Arachidonic acid metabolism—GPX1—osteoporosis	0.000338	0.00905	CbGpPWpGaD
Nabumetone—Dizziness—Alendronate—osteoporosis	0.000338	0.000987	CcSEcCtD
Nabumetone—Shock—Conjugated Estrogens—osteoporosis	0.000337	0.000985	CcSEcCtD
Nabumetone—MPO—IL23-mediated signaling events—IL6—osteoporosis	0.000337	0.00902	CbGpPWpGaD
Nabumetone—Fatigue—Pamidronate—osteoporosis	0.000336	0.000981	CcSEcCtD
Nabumetone—Gastrointestinal pain—Risedronate—osteoporosis	0.000335	0.000979	CcSEcCtD
Nabumetone—Urticaria—Ethinyl Estradiol—osteoporosis	0.000334	0.000975	CcSEcCtD
Nabumetone—Constipation—Pamidronate—osteoporosis	0.000333	0.000973	CcSEcCtD
Nabumetone—Diarrhoea—Calcitriol—osteoporosis	0.000333	0.000973	CcSEcCtD
Nabumetone—Abdominal pain—Ethinyl Estradiol—osteoporosis	0.000332	0.000971	CcSEcCtD
Nabumetone—Body temperature increased—Ethinyl Estradiol—osteoporosis	0.000332	0.000971	CcSEcCtD
Nabumetone—Dizziness—Raloxifene—osteoporosis	0.000332	0.00097	CcSEcCtD
Nabumetone—Hyperhidrosis—Conjugated Estrogens—osteoporosis	0.000331	0.000968	CcSEcCtD
Nabumetone—Flatulence—Estradiol—osteoporosis	0.000331	0.000967	CcSEcCtD
Nabumetone—Tension—Estradiol—osteoporosis	0.00033	0.000963	CcSEcCtD
Nabumetone—Vomiting—Estropipate—osteoporosis	0.00033	0.000963	CcSEcCtD
Nabumetone—Dizziness—Ibandronate—osteoporosis	0.000329	0.000961	CcSEcCtD
Nabumetone—Rash—Estropipate—osteoporosis	0.000327	0.000955	CcSEcCtD
Nabumetone—Dermatitis—Estropipate—osteoporosis	0.000327	0.000954	CcSEcCtD
Nabumetone—Anorexia—Conjugated Estrogens—osteoporosis	0.000326	0.000954	CcSEcCtD
Nabumetone—Nervousness—Estradiol—osteoporosis	0.000326	0.000953	CcSEcCtD
Nabumetone—Urticaria—Risedronate—osteoporosis	0.000325	0.000951	CcSEcCtD
Nabumetone—Headache—Estropipate—osteoporosis	0.000325	0.000949	CcSEcCtD
Nabumetone—Vomiting—Alendronate—osteoporosis	0.000325	0.000949	CcSEcCtD
Nabumetone—Body temperature increased—Risedronate—osteoporosis	0.000324	0.000946	CcSEcCtD
Nabumetone—Abdominal pain—Risedronate—osteoporosis	0.000324	0.000946	CcSEcCtD
Nabumetone—MPO—Vitamin B12 Metabolism—TNF—osteoporosis	0.000323	0.00865	CbGpPWpGaD
Nabumetone—Rash—Alendronate—osteoporosis	0.000322	0.000941	CcSEcCtD
Nabumetone—Insomnia—Zoledronate—osteoporosis	0.000322	0.00094	CcSEcCtD
Nabumetone—Dermatitis—Alendronate—osteoporosis	0.000322	0.00094	CcSEcCtD
Nabumetone—Feeling abnormal—Pamidronate—osteoporosis	0.000321	0.000938	CcSEcCtD
Nabumetone—Headache—Alendronate—osteoporosis	0.00032	0.000935	CcSEcCtD
Nabumetone—Paraesthesia—Zoledronate—osteoporosis	0.000319	0.000933	CcSEcCtD
Nabumetone—Vomiting—Raloxifene—osteoporosis	0.000319	0.000933	CcSEcCtD
Nabumetone—Gastrointestinal pain—Pamidronate—osteoporosis	0.000318	0.000931	CcSEcCtD
Nabumetone—Dyspnoea—Zoledronate—osteoporosis	0.000317	0.000927	CcSEcCtD
Nabumetone—Rash—Raloxifene—osteoporosis	0.000317	0.000925	CcSEcCtD
Nabumetone—Dermatitis—Raloxifene—osteoporosis	0.000316	0.000924	CcSEcCtD
Nabumetone—Somnolence—Zoledronate—osteoporosis	0.000316	0.000924	CcSEcCtD
Nabumetone—Vomiting—Ibandronate—osteoporosis	0.000316	0.000924	CcSEcCtD
Nabumetone—Tremor—Estradiol—osteoporosis	0.000315	0.00092	CcSEcCtD
Nabumetone—Headache—Raloxifene—osteoporosis	0.000315	0.000919	CcSEcCtD
Nabumetone—PTGS2—C-MYB transcription factor network—WNT1—osteoporosis	0.000314	0.00841	CbGpPWpGaD
Nabumetone—Rash—Ibandronate—osteoporosis	0.000313	0.000916	CcSEcCtD
Nabumetone—Dermatitis—Ibandronate—osteoporosis	0.000313	0.000915	CcSEcCtD
Nabumetone—Dyspepsia—Zoledronate—osteoporosis	0.000313	0.000915	CcSEcCtD
Nabumetone—Ill-defined disorder—Estradiol—osteoporosis	0.000312	0.000911	CcSEcCtD
Nabumetone—Headache—Ibandronate—osteoporosis	0.000311	0.00091	CcSEcCtD
Nabumetone—Insomnia—Conjugated Estrogens—osteoporosis	0.00031	0.000905	CcSEcCtD
Nabumetone—Hypersensitivity—Ethinyl Estradiol—osteoporosis	0.00031	0.000905	CcSEcCtD
Nabumetone—Vomiting—Calcitriol—osteoporosis	0.000309	0.000904	CcSEcCtD
Nabumetone—Decreased appetite—Zoledronate—osteoporosis	0.000309	0.000904	CcSEcCtD
Nabumetone—Agitation—Estradiol—osteoporosis	0.000309	0.000902	CcSEcCtD
Nabumetone—Nausea—Estropipate—osteoporosis	0.000308	0.0009	CcSEcCtD
Nabumetone—Body temperature increased—Pamidronate—osteoporosis	0.000308	0.0009	CcSEcCtD
Nabumetone—Abdominal pain—Pamidronate—osteoporosis	0.000308	0.0009	CcSEcCtD
Nabumetone—Paraesthesia—Conjugated Estrogens—osteoporosis	0.000308	0.000899	CcSEcCtD
Nabumetone—Angioedema—Estradiol—osteoporosis	0.000307	0.000897	CcSEcCtD
Nabumetone—Rash—Calcitriol—osteoporosis	0.000307	0.000897	CcSEcCtD
Nabumetone—Fatigue—Zoledronate—osteoporosis	0.000307	0.000896	CcSEcCtD
Nabumetone—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP27A1—osteoporosis	0.000307	0.00822	CbGpPWpGaD
Nabumetone—Dermatitis—Calcitriol—osteoporosis	0.000307	0.000896	CcSEcCtD
Nabumetone—Dyspnoea—Conjugated Estrogens—osteoporosis	0.000305	0.000892	CcSEcCtD
Nabumetone—Headache—Calcitriol—osteoporosis	0.000305	0.000891	CcSEcCtD
Nabumetone—Somnolence—Conjugated Estrogens—osteoporosis	0.000304	0.00089	CcSEcCtD
Nabumetone—Constipation—Zoledronate—osteoporosis	0.000304	0.000889	CcSEcCtD
Nabumetone—Nausea—Alendronate—osteoporosis	0.000303	0.000886	CcSEcCtD
Nabumetone—Malaise—Estradiol—osteoporosis	0.000303	0.000885	CcSEcCtD
Nabumetone—CYP1A2—Oxidation by Cytochrome P450—CYP27A1—osteoporosis	0.000303	0.00811	CbGpPWpGaD
Nabumetone—Hypersensitivity—Risedronate—osteoporosis	0.000302	0.000882	CcSEcCtD
Nabumetone—Vertigo—Estradiol—osteoporosis	0.000302	0.000882	CcSEcCtD
Nabumetone—Dyspepsia—Conjugated Estrogens—osteoporosis	0.000301	0.000881	CcSEcCtD
Nabumetone—Asthenia—Ethinyl Estradiol—osteoporosis	0.000301	0.000881	CcSEcCtD
Nabumetone—Syncope—Estradiol—osteoporosis	0.000301	0.00088	CcSEcCtD
Nabumetone—Nausea—Raloxifene—osteoporosis	0.000298	0.000872	CcSEcCtD
Nabumetone—Decreased appetite—Conjugated Estrogens—osteoporosis	0.000298	0.00087	CcSEcCtD
Nabumetone—Pruritus—Ethinyl Estradiol—osteoporosis	0.000297	0.000869	CcSEcCtD
Nabumetone—Palpitations—Estradiol—osteoporosis	0.000297	0.000867	CcSEcCtD
Nabumetone—Fatigue—Conjugated Estrogens—osteoporosis	0.000295	0.000863	CcSEcCtD
Nabumetone—Nausea—Ibandronate—osteoporosis	0.000295	0.000863	CcSEcCtD
Nabumetone—Loss of consciousness—Estradiol—osteoporosis	0.000295	0.000863	CcSEcCtD
Nabumetone—Asthenia—Risedronate—osteoporosis	0.000294	0.000859	CcSEcCtD
Nabumetone—PTGS1—Biological oxidations—CYP27A1—osteoporosis	0.000294	0.00788	CbGpPWpGaD
Nabumetone—Feeling abnormal—Zoledronate—osteoporosis	0.000293	0.000857	CcSEcCtD
Nabumetone—Cough—Estradiol—osteoporosis	0.000293	0.000857	CcSEcCtD
Nabumetone—Constipation—Conjugated Estrogens—osteoporosis	0.000293	0.000856	CcSEcCtD
Nabumetone—PTGS2—Signaling mediated by p38-alpha and p38-beta—ESR1—osteoporosis	0.000293	0.00784	CbGpPWpGaD
Nabumetone—PTGS1—Overview of nanoparticle effects—TNF—osteoporosis	0.000291	0.0078	CbGpPWpGaD
Nabumetone—Gastrointestinal pain—Zoledronate—osteoporosis	0.000291	0.00085	CcSEcCtD
Nabumetone—PTGS1—Phase 1 - Functionalization of compounds—CYP19A1—osteoporosis	0.000291	0.00779	CbGpPWpGaD
Nabumetone—Hypertension—Estradiol—osteoporosis	0.00029	0.000847	CcSEcCtD
Nabumetone—Pruritus—Risedronate—osteoporosis	0.00029	0.000847	CcSEcCtD
Nabumetone—Nausea—Calcitriol—osteoporosis	0.000289	0.000845	CcSEcCtD
Nabumetone—MPO—Selenium Micronutrient Network—IL1B—osteoporosis	0.000288	0.00771	CbGpPWpGaD
Nabumetone—Diarrhoea—Ethinyl Estradiol—osteoporosis	0.000287	0.00084	CcSEcCtD
Nabumetone—Hypersensitivity—Pamidronate—osteoporosis	0.000287	0.000838	CcSEcCtD
Nabumetone—Anxiety—Estradiol—osteoporosis	0.000285	0.000833	CcSEcCtD
Nabumetone—Urticaria—Zoledronate—osteoporosis	0.000283	0.000826	CcSEcCtD
Nabumetone—Discomfort—Estradiol—osteoporosis	0.000283	0.000826	CcSEcCtD
Nabumetone—Body temperature increased—Zoledronate—osteoporosis	0.000281	0.000822	CcSEcCtD
Nabumetone—Abdominal pain—Zoledronate—osteoporosis	0.000281	0.000822	CcSEcCtD
Nabumetone—Diarrhoea—Risedronate—osteoporosis	0.00028	0.000819	CcSEcCtD
Nabumetone—Gastrointestinal pain—Conjugated Estrogens—osteoporosis	0.00028	0.000818	CcSEcCtD
Nabumetone—Dry mouth—Estradiol—osteoporosis	0.00028	0.000817	CcSEcCtD
Nabumetone—Asthenia—Pamidronate—osteoporosis	0.000279	0.000817	CcSEcCtD
Nabumetone—Dizziness—Ethinyl Estradiol—osteoporosis	0.000278	0.000812	CcSEcCtD
Nabumetone—Confusional state—Estradiol—osteoporosis	0.000276	0.000808	CcSEcCtD
Nabumetone—Pruritus—Pamidronate—osteoporosis	0.000276	0.000805	CcSEcCtD
Nabumetone—Anaphylactic shock—Estradiol—osteoporosis	0.000274	0.000801	CcSEcCtD
Nabumetone—Oedema—Estradiol—osteoporosis	0.000274	0.000801	CcSEcCtD
Nabumetone—Urticaria—Conjugated Estrogens—osteoporosis	0.000272	0.000795	CcSEcCtD
Nabumetone—Dizziness—Risedronate—osteoporosis	0.000271	0.000792	CcSEcCtD
Nabumetone—Abdominal pain—Conjugated Estrogens—osteoporosis	0.000271	0.000791	CcSEcCtD
Nabumetone—Body temperature increased—Conjugated Estrogens—osteoporosis	0.000271	0.000791	CcSEcCtD
Nabumetone—Shock—Estradiol—osteoporosis	0.00027	0.000788	CcSEcCtD
Nabumetone—PTGS2—Arachidonic acid metabolism—GPX1—osteoporosis	0.000268	0.00718	CbGpPWpGaD
Nabumetone—Vomiting—Ethinyl Estradiol—osteoporosis	0.000267	0.000781	CcSEcCtD
Nabumetone—Diarrhoea—Pamidronate—osteoporosis	0.000266	0.000779	CcSEcCtD
Nabumetone—Hyperhidrosis—Estradiol—osteoporosis	0.000265	0.000774	CcSEcCtD
Nabumetone—Rash—Ethinyl Estradiol—osteoporosis	0.000265	0.000774	CcSEcCtD
Nabumetone—Dermatitis—Ethinyl Estradiol—osteoporosis	0.000265	0.000773	CcSEcCtD
Nabumetone—Headache—Ethinyl Estradiol—osteoporosis	0.000263	0.000769	CcSEcCtD
Nabumetone—MPO—Folate Metabolism—TNF—osteoporosis	0.000263	0.00704	CbGpPWpGaD
Nabumetone—Hypersensitivity—Zoledronate—osteoporosis	0.000262	0.000766	CcSEcCtD
Nabumetone—MPO—Vitamin B12 Metabolism—IL6—osteoporosis	0.000261	0.00698	CbGpPWpGaD
Nabumetone—Vomiting—Risedronate—osteoporosis	0.00026	0.000761	CcSEcCtD
Nabumetone—Rash—Risedronate—osteoporosis	0.000258	0.000755	CcSEcCtD
Nabumetone—Dermatitis—Risedronate—osteoporosis	0.000258	0.000754	CcSEcCtD
Nabumetone—Dizziness—Pamidronate—osteoporosis	0.000258	0.000753	CcSEcCtD
Nabumetone—Headache—Risedronate—osteoporosis	0.000257	0.00075	CcSEcCtD
Nabumetone—Asthenia—Zoledronate—osteoporosis	0.000255	0.000746	CcSEcCtD
Nabumetone—Hypersensitivity—Conjugated Estrogens—osteoporosis	0.000252	0.000737	CcSEcCtD
Nabumetone—Pruritus—Zoledronate—osteoporosis	0.000252	0.000735	CcSEcCtD
Nabumetone—Nausea—Ethinyl Estradiol—osteoporosis	0.00025	0.000729	CcSEcCtD
Nabumetone—CYP1A2—Phase 1 - Functionalization of compounds—CYP27A1—osteoporosis	0.000249	0.00666	CbGpPWpGaD
Nabumetone—Insomnia—Estradiol—osteoporosis	0.000248	0.000725	CcSEcCtD
Nabumetone—Vomiting—Pamidronate—osteoporosis	0.000248	0.000724	CcSEcCtD
Nabumetone—Paraesthesia—Estradiol—osteoporosis	0.000246	0.000719	CcSEcCtD
Nabumetone—Asthenia—Conjugated Estrogens—osteoporosis	0.000246	0.000718	CcSEcCtD
Nabumetone—Rash—Pamidronate—osteoporosis	0.000246	0.000718	CcSEcCtD
Nabumetone—Dermatitis—Pamidronate—osteoporosis	0.000245	0.000717	CcSEcCtD
Nabumetone—Dyspnoea—Estradiol—osteoporosis	0.000244	0.000714	CcSEcCtD
Nabumetone—Headache—Pamidronate—osteoporosis	0.000244	0.000713	CcSEcCtD
Nabumetone—Somnolence—Estradiol—osteoporosis	0.000244	0.000712	CcSEcCtD
Nabumetone—Diarrhoea—Zoledronate—osteoporosis	0.000243	0.000711	CcSEcCtD
Nabumetone—Nausea—Risedronate—osteoporosis	0.000243	0.000711	CcSEcCtD
Nabumetone—Pruritus—Conjugated Estrogens—osteoporosis	0.000242	0.000708	CcSEcCtD
Nabumetone—Dyspepsia—Estradiol—osteoporosis	0.000241	0.000705	CcSEcCtD
Nabumetone—Decreased appetite—Estradiol—osteoporosis	0.000238	0.000696	CcSEcCtD
Nabumetone—Fatigue—Estradiol—osteoporosis	0.000236	0.000691	CcSEcCtD
Nabumetone—Dizziness—Zoledronate—osteoporosis	0.000235	0.000687	CcSEcCtD
Nabumetone—PTGS2—Aryl Hydrocarbon Receptor—ESR1—osteoporosis	0.000235	0.0063	CbGpPWpGaD
Nabumetone—PTGS1—Overview of nanoparticle effects—IL6—osteoporosis	0.000235	0.00629	CbGpPWpGaD
Nabumetone—Constipation—Estradiol—osteoporosis	0.000234	0.000685	CcSEcCtD
Nabumetone—Diarrhoea—Conjugated Estrogens—osteoporosis	0.000234	0.000685	CcSEcCtD
Nabumetone—MPO—C-MYB transcription factor network—MYC—osteoporosis	0.000233	0.00623	CbGpPWpGaD
Nabumetone—Nausea—Pamidronate—osteoporosis	0.000231	0.000676	CcSEcCtD
Nabumetone—PTGS2—Overview of nanoparticle effects—TNF—osteoporosis	0.000231	0.00619	CbGpPWpGaD
Nabumetone—Dizziness—Conjugated Estrogens—osteoporosis	0.000226	0.000662	CcSEcCtD
Nabumetone—Vomiting—Zoledronate—osteoporosis	0.000226	0.000661	CcSEcCtD
Nabumetone—Feeling abnormal—Estradiol—osteoporosis	0.000226	0.00066	CcSEcCtD
Nabumetone—PTGS1—Selenium Micronutrient Network—SOD2—osteoporosis	0.000225	0.00604	CbGpPWpGaD
Nabumetone—Rash—Zoledronate—osteoporosis	0.000224	0.000655	CcSEcCtD
Nabumetone—Gastrointestinal pain—Estradiol—osteoporosis	0.000224	0.000655	CcSEcCtD
Nabumetone—Dermatitis—Zoledronate—osteoporosis	0.000224	0.000655	CcSEcCtD
Nabumetone—Headache—Zoledronate—osteoporosis	0.000223	0.000651	CcSEcCtD
Nabumetone—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—osteoporosis	0.000222	0.00594	CbGpPWpGaD
Nabumetone—Vomiting—Conjugated Estrogens—osteoporosis	0.000218	0.000636	CcSEcCtD
Nabumetone—Urticaria—Estradiol—osteoporosis	0.000218	0.000636	CcSEcCtD
Nabumetone—Abdominal pain—Estradiol—osteoporosis	0.000217	0.000633	CcSEcCtD
Nabumetone—Body temperature increased—Estradiol—osteoporosis	0.000217	0.000633	CcSEcCtD
Nabumetone—Rash—Conjugated Estrogens—osteoporosis	0.000216	0.000631	CcSEcCtD
Nabumetone—Dermatitis—Conjugated Estrogens—osteoporosis	0.000216	0.000631	CcSEcCtD
Nabumetone—PTGS1—Selenium Micronutrient Network—GPX1—osteoporosis	0.000215	0.00576	CbGpPWpGaD
Nabumetone—Headache—Conjugated Estrogens—osteoporosis	0.000215	0.000627	CcSEcCtD
Nabumetone—MPO—Folate Metabolism—IL6—osteoporosis	0.000212	0.00568	CbGpPWpGaD
Nabumetone—Nausea—Zoledronate—osteoporosis	0.000211	0.000617	CcSEcCtD
Nabumetone—MPO—Selenium Micronutrient Network—TNF—osteoporosis	0.000209	0.00559	CbGpPWpGaD
Nabumetone—Nausea—Conjugated Estrogens—osteoporosis	0.000203	0.000595	CcSEcCtD
Nabumetone—Hypersensitivity—Estradiol—osteoporosis	0.000202	0.00059	CcSEcCtD
Nabumetone—CYP1A2—Tryptophan metabolism—CYP19A1—osteoporosis	0.000199	0.00534	CbGpPWpGaD
Nabumetone—PTGS1—Selenium Micronutrient Network—MTHFR—osteoporosis	0.000198	0.00531	CbGpPWpGaD
Nabumetone—Asthenia—Estradiol—osteoporosis	0.000197	0.000575	CcSEcCtD
Nabumetone—PTGS1—Metabolism of lipids and lipoproteins—FDPS—osteoporosis	0.000196	0.00527	CbGpPWpGaD
Nabumetone—Pruritus—Estradiol—osteoporosis	0.000194	0.000567	CcSEcCtD
Nabumetone—Diarrhoea—Estradiol—osteoporosis	0.000188	0.000548	CcSEcCtD
Nabumetone—PTGS2—Overview of nanoparticle effects—IL6—osteoporosis	0.000186	0.005	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism of lipids and lipoproteins—GPD2—osteoporosis	0.000186	0.00499	CbGpPWpGaD
Nabumetone—Dizziness—Estradiol—osteoporosis	0.000181	0.00053	CcSEcCtD
Nabumetone—PTGS2—Selenium Micronutrient Network—SOD2—osteoporosis	0.000179	0.00479	CbGpPWpGaD
Nabumetone—PTGS1—Phase 1 - Functionalization of compounds—POMC—osteoporosis	0.000175	0.00468	CbGpPWpGaD
Nabumetone—PTGS2—Integrated Pancreatic Cancer Pathway—RAP1A—osteoporosis	0.000174	0.00467	CbGpPWpGaD
Nabumetone—Vomiting—Estradiol—osteoporosis	0.000174	0.000509	CcSEcCtD
Nabumetone—Rash—Estradiol—osteoporosis	0.000173	0.000505	CcSEcCtD
Nabumetone—Dermatitis—Estradiol—osteoporosis	0.000173	0.000505	CcSEcCtD
Nabumetone—Headache—Estradiol—osteoporosis	0.000172	0.000502	CcSEcCtD
Nabumetone—PTGS2—Selenium Micronutrient Network—GPX1—osteoporosis	0.000171	0.00457	CbGpPWpGaD
Nabumetone—MPO—Selenium Micronutrient Network—IL6—osteoporosis	0.000168	0.00451	CbGpPWpGaD
Nabumetone—Nausea—Estradiol—osteoporosis	0.000163	0.000476	CcSEcCtD
Nabumetone—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP19A1—osteoporosis	0.000161	0.00432	CbGpPWpGaD
Nabumetone—CYP1A2—Oxidation by Cytochrome P450—CYP19A1—osteoporosis	0.000159	0.00426	CbGpPWpGaD
Nabumetone—PTGS2—Defective AMN causes hereditary megaloblastic anemia 1—MTHFR—osteoporosis	0.000159	0.00426	CbGpPWpGaD
Nabumetone—PTGS2—Selenium Micronutrient Network—MTHFR—osteoporosis	0.000157	0.00422	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism of lipids and lipoproteins—FDPS—osteoporosis	0.000156	0.00418	CbGpPWpGaD
Nabumetone—PTGS1—Biological oxidations—CYP19A1—osteoporosis	0.000154	0.00414	CbGpPWpGaD
Nabumetone—CYP1A2—Arachidonic acid metabolism—GPX1—osteoporosis	0.000152	0.00407	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism of lipids and lipoproteins—GPD2—osteoporosis	0.000148	0.00396	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism of lipids and lipoproteins—OXCT1—osteoporosis	0.000145	0.00388	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism of lipids and lipoproteins—MGLL—osteoporosis	0.000141	0.00378	CbGpPWpGaD
Nabumetone—CYP1A2—Aryl Hydrocarbon Receptor—ESR1—osteoporosis	0.000133	0.00357	CbGpPWpGaD
Nabumetone—CYP1A2—Biological oxidations—CYP27A1—osteoporosis	0.000132	0.00354	CbGpPWpGaD
Nabumetone—CYP1A2—Phase 1 - Functionalization of compounds—CYP19A1—osteoporosis	0.000131	0.0035	CbGpPWpGaD
Nabumetone—CYP1A2—Metapathway biotransformation—CYP27A1—osteoporosis	0.00013	0.00349	CbGpPWpGaD
Nabumetone—PTGS2—Integrated Pancreatic Cancer Pathway—ESR2—osteoporosis	0.000124	0.00333	CbGpPWpGaD
Nabumetone—PTGS2—Aryl Hydrocarbon Receptor—MYC—osteoporosis	0.000122	0.00328	CbGpPWpGaD
Nabumetone—PTGS1—Selenium Micronutrient Network—IL1B—osteoporosis	0.000118	0.00315	CbGpPWpGaD
Nabumetone—PTGS2—Spinal Cord Injury—LEP—osteoporosis	0.000116	0.00311	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism of lipids and lipoproteins—OXCT1—osteoporosis	0.000115	0.00308	CbGpPWpGaD
Nabumetone—PTGS2—Aryl Hydrocarbon Receptor—TNF—osteoporosis	0.000114	0.00305	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism of lipids and lipoproteins—CYP27A1—osteoporosis	0.000113	0.00302	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism of lipids and lipoproteins—MGLL—osteoporosis	0.000112	0.003	CbGpPWpGaD
Nabumetone—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—TNF—osteoporosis	0.000107	0.00286	CbGpPWpGaD
Nabumetone—CYP1A2—Cytochrome P450 - arranged by substrate type—POMC—osteoporosis	9.68e-05	0.00259	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism of lipids and lipoproteins—P4HB—osteoporosis	9.6e-05	0.00257	CbGpPWpGaD
Nabumetone—PTGS2—Selenium Micronutrient Network—IL1B—osteoporosis	9.34e-05	0.0025	CbGpPWpGaD
Nabumetone—PTGS1—Biological oxidations—POMC—osteoporosis	9.28e-05	0.00249	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism of lipids and lipoproteins—CYP27A1—osteoporosis	8.96e-05	0.0024	CbGpPWpGaD
Nabumetone—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL1B—osteoporosis	8.88e-05	0.00238	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism of lipids and lipoproteins—FDPS—osteoporosis	8.83e-05	0.00237	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—PKM—osteoporosis	8.75e-05	0.00234	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—FDPS—osteoporosis	8.75e-05	0.00234	CbGpPWpGaD
Nabumetone—PTGS1—Selenium Micronutrient Network—TNF—osteoporosis	8.54e-05	0.00229	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism of lipids and lipoproteins—GPD2—osteoporosis	8.37e-05	0.00224	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—PGLS—osteoporosis	8.3e-05	0.00222	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—GPD2—osteoporosis	8.3e-05	0.00222	CbGpPWpGaD
Nabumetone—PTGS2—Disease—SOST—osteoporosis	8.29e-05	0.00222	CbGpPWpGaD
Nabumetone—PTGS2—Disease—PKM—osteoporosis	8.29e-05	0.00222	CbGpPWpGaD
Nabumetone—PTGS2—Disease—ANTXR2—osteoporosis	7.86e-05	0.00211	CbGpPWpGaD
Nabumetone—PTGS2—Disease—PGLS—osteoporosis	7.86e-05	0.00211	CbGpPWpGaD
Nabumetone—CYP1A2—Phase 1 - Functionalization of compounds—POMC—osteoporosis	7.85e-05	0.0021	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism of lipids and lipoproteins—P4HB—osteoporosis	7.62e-05	0.00204	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—ATIC—osteoporosis	7.59e-05	0.00203	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—PNP—osteoporosis	7.59e-05	0.00203	CbGpPWpGaD
Nabumetone—PTGS2—C-MYB transcription factor network—MYC—osteoporosis	7.55e-05	0.00202	CbGpPWpGaD
Nabumetone—PTGS2—Integrated Pancreatic Cancer Pathway—ESR1—osteoporosis	7.53e-05	0.00202	CbGpPWpGaD
Nabumetone—PTGS2—Spinal Cord Injury—IL1B—osteoporosis	7.39e-05	0.00198	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—PKM—osteoporosis	6.95e-05	0.00186	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—FDPS—osteoporosis	6.95e-05	0.00186	CbGpPWpGaD
Nabumetone—CYP1A2—Biological oxidations—CYP19A1—osteoporosis	6.93e-05	0.00186	CbGpPWpGaD
Nabumetone—CYP1A2—Aryl Hydrocarbon Receptor—MYC—osteoporosis	6.92e-05	0.00185	CbGpPWpGaD
Nabumetone—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TGFB1—osteoporosis	6.9e-05	0.00185	CbGpPWpGaD
Nabumetone—PTGS1—Selenium Micronutrient Network—IL6—osteoporosis	6.89e-05	0.00185	CbGpPWpGaD
Nabumetone—CYP1A2—Metapathway biotransformation—CYP19A1—osteoporosis	6.84e-05	0.00183	CbGpPWpGaD
Nabumetone—PTGS2—Selenium Micronutrient Network—TNF—osteoporosis	6.78e-05	0.00182	CbGpPWpGaD
Nabumetone—PTGS2—Disease—GSN—osteoporosis	6.69e-05	0.00179	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—GPD2—osteoporosis	6.59e-05	0.00176	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—PGLS—osteoporosis	6.59e-05	0.00176	CbGpPWpGaD
Nabumetone—PTGS2—Integrated Pancreatic Cancer Pathway—IGF1—osteoporosis	6.51e-05	0.00175	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism of lipids and lipoproteins—OXCT1—osteoporosis	6.51e-05	0.00174	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—OXCT1—osteoporosis	6.45e-05	0.00173	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—CA2—osteoporosis	6.45e-05	0.00173	CbGpPWpGaD
Nabumetone—CYP1A2—Aryl Hydrocarbon Receptor—TNF—osteoporosis	6.45e-05	0.00173	CbGpPWpGaD
Nabumetone—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—osteoporosis	6.45e-05	0.00173	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism of lipids and lipoproteins—MGLL—osteoporosis	6.34e-05	0.0017	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—MGLL—osteoporosis	6.29e-05	0.00168	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—PNP—osteoporosis	6.02e-05	0.00161	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—ATIC—osteoporosis	6.02e-05	0.00161	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism of lipids and lipoproteins—CYP19A1—osteoporosis	5.93e-05	0.00159	CbGpPWpGaD
Nabumetone—PTGS2—Disease—LRP5—osteoporosis	5.82e-05	0.00156	CbGpPWpGaD
Nabumetone—PTGS2—Spinal Cord Injury—MYC—osteoporosis	5.76e-05	0.00154	CbGpPWpGaD
Nabumetone—PTGS2—Spinal Cord Injury—TGFB1—osteoporosis	5.74e-05	0.00154	CbGpPWpGaD
Nabumetone—PTGS2—Disease—LRP6—osteoporosis	5.56e-05	0.00149	CbGpPWpGaD
Nabumetone—PTGS2—Selenium Micronutrient Network—IL6—osteoporosis	5.47e-05	0.00147	CbGpPWpGaD
Nabumetone—PTGS2—Spinal Cord Injury—TNF—osteoporosis	5.36e-05	0.00144	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—IDH2—osteoporosis	5.35e-05	0.00143	CbGpPWpGaD
Nabumetone—PTGS2—Disease—LTF—osteoporosis	5.34e-05	0.00143	CbGpPWpGaD
Nabumetone—PTGS2—Disease—RPL24—osteoporosis	5.34e-05	0.00143	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—OXCT1—osteoporosis	5.12e-05	0.00137	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—CA2—osteoporosis	5.12e-05	0.00137	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism of lipids and lipoproteins—CYP27A1—osteoporosis	5.07e-05	0.00136	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—CYP27A1—osteoporosis	5.03e-05	0.00135	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—MGLL—osteoporosis	4.99e-05	0.00134	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—ACP5—osteoporosis	4.89e-05	0.00131	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism of lipids and lipoproteins—GPX1—osteoporosis	4.83e-05	0.00129	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism of lipids and lipoproteins—CYP19A1—osteoporosis	4.71e-05	0.00126	CbGpPWpGaD
Nabumetone—PTGS2—Disease—ACP5—osteoporosis	4.63e-05	0.00124	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—TPI1—osteoporosis	4.54e-05	0.00122	CbGpPWpGaD
Nabumetone—PTGS2—Spinal Cord Injury—IL6—osteoporosis	4.33e-05	0.00116	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism of lipids and lipoproteins—P4HB—osteoporosis	4.31e-05	0.00116	CbGpPWpGaD
Nabumetone—PTGS2—Disease—TPI1—osteoporosis	4.31e-05	0.00115	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—P4HB—osteoporosis	4.27e-05	0.00115	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—IDH2—osteoporosis	4.24e-05	0.00114	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—GAPDH—osteoporosis	4.19e-05	0.00112	CbGpPWpGaD
Nabumetone—CYP1A2—Biological oxidations—POMC—osteoporosis	4.17e-05	0.00112	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—RAP1A—osteoporosis	4.09e-05	0.00109	CbGpPWpGaD
Nabumetone—PTGS2—Disease—P4HB—osteoporosis	4.05e-05	0.00109	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—CYP27A1—osteoporosis	3.99e-05	0.00107	CbGpPWpGaD
Nabumetone—PTGS2—Disease—GAPDH—osteoporosis	3.98e-05	0.00107	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—FDPS—osteoporosis	3.93e-05	0.00105	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—PKM—osteoporosis	3.93e-05	0.00105	CbGpPWpGaD
Nabumetone—PTGS2—Integrated Pancreatic Cancer Pathway—MYC—osteoporosis	3.92e-05	0.00105	CbGpPWpGaD
Nabumetone—PTGS2—Integrated Pancreatic Cancer Pathway—TGFB1—osteoporosis	3.91e-05	0.00105	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—ACP5—osteoporosis	3.88e-05	0.00104	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism of lipids and lipoproteins—GPX1—osteoporosis	3.83e-05	0.00103	CbGpPWpGaD
Nabumetone—PTGS2—Disease—NFATC1—osteoporosis	3.78e-05	0.00101	CbGpPWpGaD
Nabumetone—PTGS2—Disease—DKK1—osteoporosis	3.75e-05	0.001	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—PGLS—osteoporosis	3.73e-05	0.000999	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—GPD2—osteoporosis	3.73e-05	0.000999	CbGpPWpGaD
Nabumetone—PTGS2—Integrated Pancreatic Cancer Pathway—TNF—osteoporosis	3.65e-05	0.000977	CbGpPWpGaD
Nabumetone—PTGS2—Disease—WNT1—osteoporosis	3.61e-05	0.000967	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—TPI1—osteoporosis	3.61e-05	0.000967	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism of lipids and lipoproteins—POMC—osteoporosis	3.56e-05	0.000955	CbGpPWpGaD
Nabumetone—PTGS2—Disease—FGA—osteoporosis	3.51e-05	0.000941	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—ATIC—osteoporosis	3.41e-05	0.000913	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—PNP—osteoporosis	3.41e-05	0.000913	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—P4HB—osteoporosis	3.39e-05	0.000909	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—GAPDH—osteoporosis	3.33e-05	0.000892	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—ENO1—osteoporosis	3.3e-05	0.000885	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—PSMA2—osteoporosis	3.25e-05	0.000872	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—PSMA5—osteoporosis	3.25e-05	0.000872	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—RAP1A—osteoporosis	3.24e-05	0.000869	CbGpPWpGaD
Nabumetone—PTGS2—Disease—ENO1—osteoporosis	3.13e-05	0.000839	CbGpPWpGaD
Nabumetone—PTGS2—Disease—PSMA5—osteoporosis	3.08e-05	0.000827	CbGpPWpGaD
Nabumetone—PTGS2—Disease—PSMA2—osteoporosis	3.08e-05	0.000827	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—OXCT1—osteoporosis	2.9e-05	0.000777	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—CA2—osteoporosis	2.9e-05	0.000777	CbGpPWpGaD
Nabumetone—PTGS2—Disease—CALCA—osteoporosis	2.87e-05	0.00077	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism of lipids and lipoproteins—POMC—osteoporosis	2.83e-05	0.000758	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—MGLL—osteoporosis	2.82e-05	0.000757	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism of lipids and lipoproteins—CYP19A1—osteoporosis	2.66e-05	0.000714	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—CYP19A1—osteoporosis	2.64e-05	0.000707	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—ENO1—osteoporosis	2.62e-05	0.000703	CbGpPWpGaD
Nabumetone—PTGS2—Disease—KL—osteoporosis	2.61e-05	0.000699	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—PSMA2—osteoporosis	2.58e-05	0.000692	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—PSMA5—osteoporosis	2.58e-05	0.000692	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—IDH2—osteoporosis	2.4e-05	0.000643	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—CYP27A1—osteoporosis	2.26e-05	0.000605	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—ACP5—osteoporosis	2.2e-05	0.000589	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism of lipids and lipoproteins—GPX1—osteoporosis	2.17e-05	0.000581	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—ADCY5—osteoporosis	2.16e-05	0.000578	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—GPX1—osteoporosis	2.15e-05	0.000576	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—CYP19A1—osteoporosis	2.1e-05	0.000562	CbGpPWpGaD
Nabumetone—PTGS2—Disease—ADCY5—osteoporosis	2.04e-05	0.000548	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—TPI1—osteoporosis	2.04e-05	0.000547	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—MTHFR—osteoporosis	1.98e-05	0.000532	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—P4HB—osteoporosis	1.92e-05	0.000514	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—GAPDH—osteoporosis	1.88e-05	0.000505	CbGpPWpGaD
Nabumetone—PTGS2—Disease—MTHFR—osteoporosis	1.88e-05	0.000504	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—RAP1A—osteoporosis	1.84e-05	0.000492	CbGpPWpGaD
Nabumetone—PTGS2—Disease—IRS2—osteoporosis	1.79e-05	0.000479	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—ADCY5—osteoporosis	1.71e-05	0.000459	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—GPX1—osteoporosis	1.71e-05	0.000457	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism of lipids and lipoproteins—POMC—osteoporosis	1.6e-05	0.000429	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—POMC—osteoporosis	1.59e-05	0.000425	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—MTHFR—osteoporosis	1.57e-05	0.000422	CbGpPWpGaD
Nabumetone—PTGS2—Disease—IRS1—osteoporosis	1.56e-05	0.000419	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—ENO1—osteoporosis	1.48e-05	0.000398	CbGpPWpGaD
Nabumetone—PTGS2—Disease—IL6R—osteoporosis	1.47e-05	0.000393	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—PSMA5—osteoporosis	1.46e-05	0.000392	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—PSMA2—osteoporosis	1.46e-05	0.000392	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—POMC—osteoporosis	1.26e-05	0.000338	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—CYP19A1—osteoporosis	1.19e-05	0.000318	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—ADCY5—osteoporosis	9.69e-06	0.00026	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—GPX1—osteoporosis	9.66e-06	0.000259	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—MTHFR—osteoporosis	8.91e-06	0.000239	CbGpPWpGaD
Nabumetone—PTGS2—Disease—MYC—osteoporosis	8.69e-06	0.000233	CbGpPWpGaD
Nabumetone—PTGS2—Disease—TGFB1—osteoporosis	8.67e-06	0.000232	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—POMC—osteoporosis	7.13e-06	0.000191	CbGpPWpGaD
Nabumetone—PTGS2—Disease—IL6—osteoporosis	6.54e-06	0.000175	CbGpPWpGaD
